Literature DB >> 7663035

Recent advances: the cytochrome P450 enzymes.

R L Slaughter1, D J Edwards.   

Abstract

Successful application of information on cytochrome P450 to prevent drug interactions and improve the therapeutic risk: benefit ratio can occur only if we know which enzyme is responsible for the metabolism of a drug. Until recently, this information was not usually available when new drugs reached the market. It is not enough to know the fraction of a dose metabolized versus excreted unchanged or the metabolic pathways by which a compound is degraded. Studies conducted during drug development must identify the enzyme or enzymes involved in the metabolism of new drugs. In addition, the ability of new drugs to inhibit or induce the activity of the key P450 enzymes must be known if we are to take full advantage of our current knowledge of how the cytochrome P450 system works.

Mesh:

Substances:

Year:  1995        PMID: 7663035     DOI: 10.1177/106002809502900612

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  35 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Authors:  Kwee Poo Yeo; Stephen L Lowe; Ming Tung Lim; James R Voelker; Jennifer L Burkey; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

4.  Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.

Authors:  Curtis E Haas; Daniel Brazeau; Denise Cloen; Brent M Booker; Valerie Frerichs; Colleen Zaranek; Reginald F Frye; Thomas Kufel
Journal:  Eur J Clin Pharmacol       Date:  2005-07-22       Impact factor: 2.953

5.  Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.

Authors:  F T Aweeka; C Hu; L Huang; B M Best; A Stek; P Lizak; S K Burchett; J S Read; H Watts; M Mirochnick; E V Capparelli
Journal:  HIV Med       Date:  2014-11-18       Impact factor: 3.180

6.  Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.

Authors:  Gudrun Hefner; Stefan Unterecker; Mohamed E E Shams; Margarete Wolf; Tanja Falter; Ekkehard Haen; Christoph Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2015-05-05       Impact factor: 3.575

7.  Structural and biochemical studies of a recombinant 25.5 kDa glutathione transferase of Taenia solium metacestode (rTs25GST1-1).

Authors:  Aramis Roldan; Anayetzin Torres-Rivera; Abraham Landa
Journal:  Parasitol Res       Date:  2013-08-20       Impact factor: 2.289

Review 8.  Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

Authors:  Thomas Unger; Elena Kaschina
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Authors:  Sule Kalkan; Mukaddes Gumustekin; Oguz Aygoren; Yesim Tuncok; Ayse Gelal; Hulya Guven
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.